# Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer

> **NCT00691730** · — · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 52 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00691730
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-07
- **Final completion:** 2019-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2021-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00691730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00691730, "Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00691730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*